Adverse effects of imatinib in children with chronic myelogenous leukemia
© 2016 Japan Pediatric Society Background: Imatinib mesylate (IM) is a selective tyrosine kinase inhibitor and is approved for indefinite treatment of pediatric chronic myelogenous leukemia (CML). Potential side-effects regarding growth failure and bone metabolism have been reported but data are sti...
Saved in:
| Main Authors: | , , , , |
|---|---|
| 格式: | 雜誌 |
| 出版: |
2018
|
| 主題: | |
| 在線閱讀: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85005810433&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/57736 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
成為第一個發表評論!